オリゴヌクレオチド合成の世界市場：2024年～2031年

レポート概要

オリゴヌクレオチド合成の世界市場は2023年に75億米ドルに達し、2031年には152億米ドルに達する見込みで、予測期間2024-2031年にCAGRで9.0%の成長が予測されています。

オリゴヌクレオチド合成は、分子生物学、バイオテクノロジー、および治療用途のために、オリゴヌクレオチドとして知られる短いヌクレオチド配列を作成する化学プロセスです。これらの合成DNAまたはRNA鎖は、遺伝子分析、診断、治療薬に使用されます。この技術の進歩は、個別化医療、RNAベースのワクチン、遺伝性疾患の標的療法につながっています。オリゴヌクレオチド合成市場は、ゲノミクス、バイオ医薬品、診断の革新により拡大を続けています。

市場力学：

促進要因と抑制要因

製薬・バイオテクノロジー企業への投資の増加

オリゴヌクレオチド合成市場は、イノベーションと治療法の探求を促進する政府資金や調査からの多額の投資によって後押しされています。しかし、コストの上昇や標準化されたガイドラインの欠如といった課題が潜在的な障害となっています。したがって、利害関係者は近い将来、市場の成長ポテンシャルを十分に活用するために、こうした市場力学をうまく操る必要があります。

例えば、2024年6月、GSK plcは、サンディエゴを拠点とし、オリゴヌクレオチド治療薬の可能性を最大限に引き出すことに特化した非公開バイオテクノロジー企業であるElsie Biotechnologiesを、最大5,000万米ドル（約3,900万ポンド）で買収したと発表しました。オリゴヌクレオチドには遺伝子発現を調節するユニークな能力があるため、従来の低分子化合物や生物製剤では対応できない治療標的のかなりの部分に対処できる魅力的な方法です。

コスト削減

オリゴヌクレオチド合成市場は、コストの浸食、治療用オリゴのガイドラインの不確実性、統一されたガイドラインの欠如による課題に直面しています。これらの要因は利益率や市場の持続性に影響を与え、オリゴヌクレオチド合成技術のシームレスな進歩を妨げる可能性があります。分子診断と臨床応用における持続的成長のためには、利害関係者がこれらの課題に効果的に対処することが極めて重要です。

市場セグメンテーション

世界のオリゴヌクレオチド合成市場は、製品タイプ、用途、エンドユーザー、地域によって区分されます。

製品タイプ別の試薬は、オリゴヌクレオチド合成市場シェアの約41.3%を占めます。

製品タイプ別の試薬のシェアは約41.3％。世界のオリゴヌクレオチド合成市場は、ホスホルアミダイト、溶媒、触媒、キャッピング剤などの試薬に大きく依存しており、合成プロセスの効率、精度、収率をコントロールしています。高品質の試薬はオリゴヌクレオチド鎖の忠実性を保証し、エラーを最小限に抑えます。遺伝子編集、診断、治療における精密で信頼性の高いオリゴヌクレオチドへの需要の高まりにより、合成試薬の市場は大きく拡大しています。オリゴヌクレオチドを用いた研究の成功と新規治療薬の開発は、試薬の品質向上に直結しています。

例えば、2024年9月、Emp Biotech社は、同社の高品質オリゴヌクレオチド合成試薬を英国とアイルランドで販売するため、Atom Scientific社と提携し、同社のオリゴヌクレオチド合成製品の独占販売パートナーシップを結びました。

市場の地域別シェア

北米は予測期間を通じて市場シェア全体の約38.4%を占めると予測されます。

北米は、ライフサイエンス・ヘルスケア分野における研究開発投資の増加や、様々な疾患に対する個別化治療薬の開発への注目の高まりが、同市場の大きなシェアを支える主な要因となっており、予測期間を通じて市場全体の約38.4%を占めると推定・予測されています。

例えば、2024年5月、酵素工学の主要企業であるCodexis, Inc.は、RNAベースの治療薬製造をサポートする酵素ルートによるオリゴヌクレオチドの合成に成功したと発表しました。Codexis社は、出発物質からコンジュゲーション部位を結合させた完全長オリゴヌクレオチドの酵素合成に初めて成功し、RNAi治療薬業界における代替製造法の重要なプルーフ・オブ・プロセスを提供しました。

さらに、米国がん協会は、2024年には米国で新たに2,001,140人のがん患者が発生し、611,720人ががん関連で死亡すると予測しています。新規で改良されたがん治療に対する需要が高まるにつれ、オリゴヌクレオチド合成に対する要求も高まっています。オリゴヌクレオチド合成は様々な研究や診断用途に使用されています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 製薬・バイオテクノロジー企業への投資の増加
    • 研究開発の進展
  • 抑制要因
    • コストの浸食
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• 特許分析
• PESTLE分析
• SWOT分析
• DMIオピニオン

第6章 製品タイプ別

• 試薬
• 装置
• オリゴヌクレオチド合成

第7章 用途別

• 研究
• 診断
• 治療

第8章 エンドユーザー別

• 病院
• 学術・研究機関
• 製薬・バイオテクノロジー企業
• 診断研究所

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第11章 企業プロファイル

• Thermo Fisher Scientific Inc
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Agilent Technologies Inc.
• Integrated DNA Technologies（IDT）
• LGC Biosearch Technologies
• Bio-Synthesis Inc.
• GE Healthcare（Cytiva）
• Eurofins Genomics
• TriLink BioTechnologies（a Maravai LifeSciences company）
• Merck KGaA（Sigma-Aldrich）
• ATDBio Ltd.

第12章 付録

Report Overview

Global Oligonucleotide Synthesis Market reached US$ 7.5 billion in 2023 and is expected to reach US$ 15.2 billion by 2031, growing at a CAGR of 9.0% during the forecast period 2024-2031

Oligonucleotide synthesis is the chemical process of creating short nucleotide sequences, known as oligonucleotides, for molecular biology, biotechnology, and therapeutic applications. These synthetic DNA or RNA strands are used in genetic analysis, diagnostics, and therapeutics. Advancements in this technology have led to personalized medicine, RNA-based vaccines, and targeted therapies for genetic diseases. The market for synthetic oligonucleotides continues to expand due to innovations in genomics, biopharmaceuticals, and diagnostics.

Market Dynamics: Drivers & Restraints

Increased investment in pharmaceutical and biotechnology companies

The oligonucleotide synthesis market is boosted by substantial investment from government funds and research, promoting innovation and therapeutic exploration. However, challenges like cost erosion and lack of standardized guidelines pose potential hindrances. Therefore, stakeholders must navigate these market dynamics to fully capitalize on the market's growth potential in the near future.

For instance, in June 2024, GSK plc announced that it had acquired Elsie Biotechnologies, a San Diego-based private biotechnology company dedicated to unlocking the full potential of oligonucleotide therapeutics, for up to $50 million (approximately £39 million). Oligonucleotides have a unique ability to modulate gene expression, making them an attractive modality to address a significant proportion of therapeutic targets that are not amenable to traditional small molecules or biologics.

Erosion of costs

The oligonucleotide synthesis market faces challenges due to cost erosion, uncertainty in therapeutic oligo guidelines, and a lack of unified guidelines. These factors could impact profit margins and market sustainability, hindering the seamless progression of oligonucleotide synthesis technologies. It is crucial for industry stakeholders to effectively address these challenges for sustained growth in molecular diagnostics and clinical applications.

Market Segment Analysis

The global oligonucleotide synthesis market is segmented based on product type, application, end-user, and region.

The reagents from the product type segment accounted for approximately 41.3% of the oligonucleotide synthesis market share

The reagents from the product type segment accounted for approximately 41.3%. The global oligonucleotide synthesis market relies heavily on reagents, including phosphoramidites, solvents, catalysts, and capping agents, which control the efficiency, accuracy, and yield of the synthesis process. High-quality reagents ensure the fidelity of oligonucleotide chains and minimize errors. The market for synthesis reagents has expanded significantly due to the growing demand for precise and reliable oligonucleotides in gene editing, diagnostics, and therapeutics. The success of oligonucleotide-based research and the development of novel therapeutics are directly linked to reagent quality advancements.

For instance, in September 2024, Emp Biotech partnered with Atom Scientific to distribute its high-quality oligonucleotide synthesis reagents in the UK and Ireland, marking an exclusive distribution partnership for the company's oligonucleotide synthesis products.

Market Geographical Share

North America is estimated to hold about 38.4% of the total market share throughout the forecast period

North America is estimated to hold about 38.4% of the total market share throughout the forecast period due to increasing R&D investments in the field of life sciences and healthcare and the growing focus on developing personalized therapeutics for various diseases are major factors supporting the large share of this market.

For instance, in May 2024, Codexis, Inc. a leading enzyme engineering company, announced it successfully synthesized an oligonucleotide via an enzymatic route to support RNA-based therapeutics manufacturing. Codexis has achieved the first enzymatic synthesis of a full-length oligonucleotide from starting material through the attachment of a conjugation moiety, providing a significant proof of process for alternative manufacturing methods in the RNAi therapeutics industry.

Moreover, the American Cancer Society predicts that in the year 2024, there will be 2,001,140 new cancer cases and 611,720 cancer-related deaths in the U.S. As the demand for new and improved cancer treatments increases, the requirement for synthetic oligonucleotides is growing. The synthetic oligonucleotides are used in a variety of research and diagnostic applications.

Market Segmentation

By Product Type

Reagents

Equipment

Synthesized Oligonucleotides

Oligonucleotide-based drugs

Primers

Probes

Large-scale synthesized oligonucleotides

Others

By Application

Research

PCR

QPCR

Sequencing

Gene Synthesis

Others

Diagnostics

Therapeutics

DNA & Oligonucleotide-based therapies

RNAi Oligonucleotide-based therapies

CpG Oligonucleotide-based therapies

By End User

Hospitals

Academic & Research Institutes

Pharmaceutical & Biotechnology companies

Diagnostic Laboratories

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

UK

France

Italy

Spain

Rest of Europe

South America

Brazil

Argentina

Rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Market Competitive Landscape

The major global players in the market include Thermo Fisher Scientific Inc., Agilent Technologies Inc., Integrated DNA Technologies (IDT), LGC Biosearch Technologies, Bio-Synthesis Inc., GE Healthcare (Cytiva), Eurofins Genomics, TriLink BioTechnologies (a Maravai LifeSciences company), Merck KGaA (Sigma-Aldrich), ATDBio Ltd among others.

Key Developments

In May 2024, Molecular Assemblies, Inc. a pioneer and leader in the field of enzymatic DNA synthesis, announced the launch of its Partnering Program to license Molecular Assemblies' Fully Enzymatic SynthesisTM (FESTM) technology for onsite synthesis. FES technology accelerates the production of long, pure, and accurate DNA to power a new rapidly emerging generation of therapeutics and diagnostics.

In March 2023, Ansa successfully synthesized a 1005-base-long oligonucleotide with industry-leading accuracy, marking a significant advancement in oligonucleotide synthesis. The company launched an Early Access Program for clonal synthetic genes in April 2023 to assist researchers in obtaining challenging sequences, such as the 1005 base sequence for gene therapy development, which is highly complex and requires the assembly of shorter oligonucleotides.

Why Purchase the Report?

To visualize the global oligonucleotide synthesis market segmentation based on product type, application, end-user, and region as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development.

Excel data sheet with numerous data points of the oligonucleotide synthesis market level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping available as excel consisting of key products of all the major players.

The global oligonucleotide synthesis market report would provide approximately 64 tables, 61 figures, and 186 pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product Type
• 3.2. Snippet by Application
• 3.3. Snippet by End User
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increased investment in pharmaceutical and biotechnology companies
    • 4.1.1.2. Advancements in the research and development
  • 4.1.2. Restraints
    • 4.1.2.1. Erosion of costs
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Patent Analysis
• 5.6. PESTLE Analysis
• 5.7. SWOT Analysis
• 5.8. DMI Opinion

6. By Product Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 6.1.2. Market Attractiveness Index, By Product Type
• 6.2. Reagents*
  • 6.2.1. Introduction
• 6.3. Equipment
• 6.4. Synthesized Oligonucleotides

7. By Application

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
• 7.2. Market Attractiveness Index, By Application
• 7.3. Research*
  • 7.3.1. Introduction
  • 7.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.4. Diagnostics
• 7.5. Therapeutics

8. By End User

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 8.1.2. Market Attractiveness Index, By End User
• 8.2. Hospitals*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Academic & Research Institutes
• 8.4. Pharmaceutical & Biotechnology companies
• 8.5. Diagnostic Laboratories

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. UK
    • 9.3.6.3. France
    • 9.3.6.4. Italy
    • 9.3.6.5. Spain
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. South Korea
    • 9.5.6.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Thermo Fisher Scientific Inc*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. Agilent Technologies Inc.
• 11.3. Integrated DNA Technologies (IDT)
• 11.4. LGC Biosearch Technologies
• 11.5. Bio-Synthesis Inc.
• 11.6. GE Healthcare (Cytiva)
• 11.7. Eurofins Genomics
• 11.8. TriLink BioTechnologies (a Maravai LifeSciences company)
• 11.9. Merck KGaA (Sigma-Aldrich)
• 11.10. ATDBio Ltd. (*LIST NOT EXHAUSTIVE)

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us